AIDS was the cause of the majority of deaths from HIV infection before 1996 but since the introduction of antiretroviral therapies the causes of mortality have changed considerably. In 2010, 75 % of deaths were due to diseases other than AIDS, the majority being cancers. Lung cancer is the most common in terms of both incidence and mortality. It shows specific features when compared to the general population: there is an excess risk due to heavy smoking but also probably due to immunosuppression. The age of onset is younger and the prognosis worse than in the general population. Management is difficult, partly due to the aggressive nature of the tumor and partly to co-morbidities and potential interactions between anticancer and antiretroviral therapies. A phase II therapeutic trial (IFCT-CHIVA 1001) is under way nationally.
Keywords: Cancer du poumon; Human immunodeficiency virus infection; Infection par le virus de l’immunodéficience humaine; Interactions antirétroviraux et chimiothérapie; Interactions cytotoxic chemotherapy and antiretroviral treatment; Lung cancer.
Copyright © 2013. Published by Elsevier Masson SAS.